This company has been acquired
ICVX Stock Overview
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Icosavax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.31 |
| 52 Week High | US$16.11 |
| 52 Week Low | US$4.75 |
| Beta | 1.28 |
| 1 Month Change | -0.78% |
| 3 Month Change | 50.84% |
| 1 Year Change | 68.80% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -56.22% |
Recent News & Updates
Recent updates
We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth
Jul 04
Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?
Mar 10Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?
Oct 18Icosavax GAAP EPS of -$0.57
Aug 15Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones
Jul 28Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation
Jun 22Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation
Mar 24We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely
Oct 29Shareholder Returns
| ICVX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.6% | -6.4% | -3.0% |
| 1Y | 68.8% | -11.7% | 7.5% |
Return vs Industry: ICVX exceeded the US Biotechs industry which returned 4.8% over the past year.
Return vs Market: ICVX exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| ICVX volatility | |
|---|---|
| ICVX Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ICVX's share price has been volatile over the past 3 months.
Volatility Over Time: ICVX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 60 | Adam Simpson | icosavax.com |
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target.
Icosavax, Inc. Fundamentals Summary
| ICVX fundamental statistics | |
|---|---|
| Market cap | US$777.79m |
| Earnings (TTM) | -US$96.71m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.0x
P/E RatioIs ICVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICVX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$70.04m |
| Gross Profit | -US$70.04m |
| Other Expenses | US$26.67m |
| Earnings | -US$96.71m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.90 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ICVX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/19 21:58 |
| End of Day Share Price | 2024/02/16 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Icosavax, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joshua Schimmer | Evercore ISI |
| Seamus Fernandez | Guggenheim Securities, LLC |
| Roger Song | Jefferies LLC |